Gilead Sciences Inc - GILD STOCK NEWS

Gilead Sciences announced its executives will present at several investor conferences in June 2021. Key events include the Cowen Annual Virtual Oncology Innovation Summit on May 21, Jefferies Virtual Healthcare Conference on June 1, Bernstein Annual Strategic Decisions Conference on June 2, and Goldman Sachs Annual Global Healthcare Conference on June 9. Live webcasts will be available on the company’s investor page, with replays for 30 days post-event. Gilead is a leading biopharmaceutical firm focused on innovative treatments for serious diseases globally.

Gilead Sciences (Nasdaq: GILD) will present at two upcoming investor conferences. The BofA Securities 2021 Virtual Health Care Conference is scheduled for May 13, 2021 at 2:00 p.m. ET, while the RBC Capital Markets 2021 Global Health Care Conference will take place on May 19, 2021 at 10:20 a.m. ET. Live webcasts can be found on the company's investors page, with replays available for 30 days post-presentation. Gilead is dedicated to developing treatments for life-threatening diseases and operates globally from its headquarters in Foster City, California.

Gilead Sciences, Inc. (Nasdaq: GILD) has announced a cash dividend of $0.71 per share for Q2 2021. This dividend is set to be paid on June 29, 2021, to shareholders recorded by the close of business on June 15, 2021. The company emphasizes that any future dividends will require Board approval. Gilead continues its commitment to developing innovative treatments for serious diseases globally.

Gilead Sciences reported Q1 2021 revenue of $6.4 billion, a 16% increase from 2020, driven by sales of Veklury and new oncology products. Diluted EPS rose 12% to $1.37, with non-GAAP EPS at $2.08, up 24%. Despite strong growth, sales from non-Veklury products fell 11% to $4.9 billion, mostly due to loss of exclusivity of key HIV drugs. Gilead expects 2021 revenue guidance of $23.7 billion to $25.1 billion and modified GAAP EPS guidance to $4.75 to $5.45.

Gilead Sciences (Nasdaq: GILD) is responding to the COVID-19 surge in India by offering technical support to its licensing partners. The company will enhance local manufacturing of remdesivir, approved for use in severe COVID-19 cases, and is donating at least 450,000 vials to Indian patients. Gilead’s voluntary licensing program has already provided access to the drug for over 2.3 million individuals in more than 60 countries. The company's focused efforts aim to address the urgent healthcare needs amid the crisis.

Gilead Sciences, Inc. (Nasdaq: GILD) will release its first quarter 2021 financial results on April 29, after market close. A conference call is scheduled for 4:30 p.m. Eastern Time the same day to discuss these results and provide a business update. Investors can access the live webcast through Gilead's Investors page or by dialing in with provided numbers. The webcast will be available for one year on Gilead's website. The company focuses on innovative medicines for life-threatening diseases, operating in over 35 countries worldwide.

Gilead Sciences (Nasdaq: GILD) received FDA accelerated approval for Trodelvy (sacituzumab govitecan-hziy) to treat adult patients with advanced urothelial cancer previously treated with platinum chemotherapy and PD-1/PD-L1 inhibitors. The approval is based on the Phase 2 TROPHY study, where 27.7% of 112 evaluable patients responded to the treatment, with a median response duration of 7.2 months. The approval highlights the need for new therapies in a market where the 5-year survival rate for metastatic UC is only 5.5%. However, the treatment comes with significant safety warnings related to neutropenia and diarrhea.

Gilead Sciences (Nasdaq: GILD) announced that the FDA granted full approval to Trodelvy (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have undergone two or more systemic therapies. Based on data from the Phase 3 ASCENT study, Trodelvy showed a 57% reduction in disease worsening and extended median progression-free survival (PFS) to 4.8 months, and overall survival (OS) to 11.8 months. Trodelvy may become a standard treatment for this aggressive cancer type.

Kite has submitted a supplemental Biologics License Application (sBLA) for Tecartus (brexucabtagene autoleucel) to the FDA, targeting adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The submission is supported by data from the Phase 1/2 ZUMA-3 trial. Tecartus, previously granted Breakthrough Therapy Designation, could be the first CAR T-cell therapy approved for adult ALL. Survival rates for these patients remain low, underlining the importance of this potential treatment.